Clinical trials: sponsored by British Columbia Cancer Agency
Prostate Cancer
US-CT Fusion for Post Implant Dosimetry
Post implant dosimetry is an essential part of quality assurance after permanent seed prostate brachytherapy. CT imaging is the standard of assessment but due to contouring uncertainties, MR-CT fusion is preferred.
- Trial name
- NCT03692104
- Testing
- transrectal ultrasound
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy
This study will investigate the efficacy of Degarelix, a Luteinizing Hormone Releasing Hormone (LHRH) antagonist, to reduce prostate volume prior to permanent seed prostate brachytherapy.
- Trial name
- NCT01446991
- Testing
- Degarelix
- Where
- 3 sites in Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Colorectal Cancer
Phase II Study of Perindopril and Regorafenib in mCRC
The purpose of this study is to find out what effects the combination of regorafenib and perindopril has on hand-foot skin reaction (HFSR), on high blood pressure (hypertension) and on any other types of side-effects and compare…
- Trial name
- PARICCA (NCT02651415)
- Testing
- Regorafenib, Perindopril
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- British Columbia Cancer Agency
Constipation, Cancer
Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients
This is a study to compare the efficacy and tolerability of two laxatives for treatment of opioid-induced constipation in adult outpatients with cancer treated at the British Columbia Cancer Pain and Symptom Management/Palliative…
- Trial name
- NCT01189409
- Testing
- PEG then Senna, Senna then PEG
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- British Columbia Cancer Agency
Cancer-related Pain
Subcutaneous Lidocaine For Cancer-Related Pain
This study's primary objective is to test the hypothesis that a single infusion of subcutaneous lidocaine can cause a clinically useful reduction in cancer pain within 48 hours of infusion and lasting a minimum of 7 days.
- Trial name
- NCT01384877
- Testing
- Lidocaine
- Where
- 2 sites in Canada
- Volunteers
- 33 people
- Sponsor
- British Columbia Cancer Agency
Cervical Cancer, Precancerous Condition
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
Precancerous lesions of the cervix occur frequently and are treatable. This justifies a population-based screening program. Following an abnormal Pap smear, patients are referred for a colposcopic exam to confirm the…
- Trial name
- MDC_Algo (NCT01094132)
- Testing
- Multispectral Digital Colposcope (MDC)
- Where
- 3 sites in United States, Canada
- Volunteers
- 551 people
- Sponsor
- British Columbia Cancer Agency
Radiotherapy Induced Mucositis, Head and Neck Cancer
A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer
The primary hypothesis of this study is that regular topical oral application of Manuka Honey will reduce the severity and duration of oral mucositis in patients who are undergoing mucotoxic radiation therapy for cancer treatment.
- Trial name
- NCT00615420
- Testing
- manuka honey
- Where
- 2 sites in Canada
- Volunteers
- 106 people
- Sponsor
- British Columbia Cancer Agency
Lung Cancer
Efficacy and Safety of Omega 3 Fatty Acid Supplements on Heavy Smokers
The study duration is 12 months. The initial enrollment visit will take approximately one hour. The Month 1, 3, 6, 7, 9 and 12 visits will take approximately 30 minutes each.
- Trial name
- Omega (NCT03936621)
- Testing
- Omega 3 fatty acid
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Bone Metastases From Breast or Prostate Cancer
18F-NaF PET Imaging for Bone Scintigraphy
The purpose of this study is to compare, in patients with prostate or breast cancer, the accuracy of 18F-NaF PET imaging to 99mTc whole body bone scans with single-photon emission computed tomography (SPECT).
- Trial name
- NCT01930812
- Testing
- NaF PET/CT Imaging, 99mTc-medronate whole body bone scan with SPECT, 18F-Sodium Fluoride (NaF)
- Where
- 10 sites in Canada
- Volunteers
- 286 people
- Sponsor
- British Columbia Cancer Agency
Castration Resistant Prostate Cancer
OGX-427 in Castration Resistant Prostate Cancer Patients
This study is being offered to patients who have castrate-resistant (also known as hormone-refractory) prostate cancer. The cancer has metastasized or spread outside the prostate area to other parts of the body or has recurred in…
- Trial name
- NCT01120470
- Testing
- OGX-427, Prednisone
- Where
- 6 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- British Columbia Cancer Agency
Brain Neoplasms, Malignant, Metastasis
CEST- Glucose Enhanced MRI for Metastatic Brain Tumours
This project will compare two MRI contrast agents in metastatic brain tumours in humans. More specifically, the investigators will compare the tumour contrast obtained using glucose versus the current standard gadolinium-based…
- Trial name
- NCT02796729
- Testing
- Magnetic resonance imaging, Gadovist (Gadobutrol), 50% dextrose solution
- Where
- Canada
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Brain Neoplasms, Lung Neoplasms
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology
Positron emission tomography (PET) is a nuclear medicine procedure based on the measurement of positron emission from radiolabelled tracer molecules.
- Conditions
- Brain Neoplasms, Lung Neoplasms, Lymphoma, Melanoma
- Trial name
- NCT00207298
- Testing
- Positron Emission Tomography
- Where
- Canada
- Volunteers
- 39,242 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer
Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers
This study evaluates the addition of Ki-67, Oncotype DX and MRI in the treatment of early stage breast cancer with neoadjuvant treatment. All enrolled patients will have Ki-67 and Oncotype AND/OR an MRI before and after surgery.
- Trial name
- ER (NCT03790813)
- Testing
- Intervention 1, Intervention 2
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Constipation
The Bowel Research Collaborative Data Tracking System Implementation Study
The project's primary purpose is to establish a network of Hospice Palliative Care settings using a common and consistent method of assessing and documenting bowel functioning in order to be able to carry out future collaborative…
- Trial name
- NCT00728975
- Where
- Canada
- Volunteers
- 533 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Intensity Modulated Versus Interstitial - Radiation Therapy
Purpose: The purpose of this trial is to compare two different treatment options for patients with low risk and low-tier intermediate risk prostate cancer.
- Trial name
- NCT00407875
- Testing
- Intensity Modulated External Beam Radiation Therapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Intraprostatic MAXimal Simultaneous Boost
This trial uses a type of radiotherapy called intensity modulated radiotherapy (IMRT), which is able to deliver the radiation to the prostate while delivering less dose to the surrounding normal organs compared with standard 3D…
- Trial name
- NCT00798837
- Testing
- Intraprostatic maximal simultaneous boost
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Ovarian Cancer, Primary Peritoneal Carcinoma
PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.
It is postulated that focal sensitizing radiotherapy may potentiate the effectiveness of durvalumab. The purpose of this study is to test the safety and tolerability of 2 different dose levels of focal sensitizing radiation…
- Conditions
- Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT03283943
- Testing
- Focal radiotherapy, Durvalumab
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- British Columbia Cancer Agency
Invasive Breast Cancer, Chemotherapeutic Toxicity
Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy
Taxane-induced arthralgia and myalgia syndrome (TAMS) is one of the most common side effects of taxane chemotherapy. This prospective randomized controlled trial will evaluate the efficacy of gabapentin administered…
- Conditions
- Invasive Breast Cancer, Chemotherapeutic Toxicity, Myalgia, Arthralgia
- Trial name
- NCT03566394
- Testing
- Gabapentin 300mg
- Volunteers
- 46 people
- Sponsor
- British Columbia Cancer Agency
Resectable Pancreatic Ductal Adenocarcinoma
The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma
This is a single arm, non-randomized phase II study of neoadjuvant metformin in resectable PDAC. Twenty patients will be enrolled and treated with metformin 500 mg BD for a minimum of 7 days, until 2 days prior to surgery.
- Trial name
- Metformin 001 (NCT02978547)
- Testing
- Metformin Hydrochloride 500Mg Tablet
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency
Hepatocellular Carcinoma
Hepatocellular Carcinoma Using Stereotactic Body Radiotherapy
Respiratory-gated, volumetric-modulated arc therapy will be used for the clinical development of high dose rate Stereotactic Body Radiotherapy (SBRT) in inoperable hepatocellular carcinoma (HCC).
- Trial name
- NCT01850316
- Testing
- Stereotactic Ablative Radiotherapy
- Where
- Canada
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency